Industries > Pharma > World Cancer-Treating Drugs Market Forecast 2017-2027

World Cancer-Treating Drugs Market Forecast 2017-2027

Immunotherapy, Chemotherapy, Targeted Therapy, Hormone Therapy, Leading Drugs

PUBLISHED: 14 September 2017
PAGES: 146
PRODUCT CODE: PHA0236

Clear
WOOCS 2.2.1
SKU: PHA0236 Categories: , , Tag:

The world cancer-treating drugs market is expected to grow at a CAGR of 6.6% in the second half of the forecast period. The market reached $102bn in 2016, dominated by the immunotherapy segment which held 44.1% share of the market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 194-page report you will receive 110 tables and 101 figures – all unavailable elsewhere.

The 194-page report provides clear detailed insight into the world cancer-treating drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

World cancer-treating drugs market forecasts from 2017-2027

• This report also breaks down the revenue forecast for the world cancer-treating drugs market by its leading segments:
– Immunotherapy
– Chemotherapy
– Targeted Therapy
– Hormone Therapy

Each sector is analysed and revenue forecasts presented.

• This report discusses and forecasts revenues of the top 25 anti-cancer drugs:
– Avastin
– Herceptin
– Rituxan
– Gleevec
– Revlimid
– Alimta
– Velcade
– Erbitux
– Gardasil
– Zytiga
– Xeloda
– Tarceva
– Afinitor
– Sprycel
– Tasigna
– Sutent
– Nexavar
– Xgeva
– Zoladex
– Yervoy
– Vidaza
– Treanda
– Temodar
– Faslodex
– Abraxane
– Others

• This report provides individual revenue forecasts to 2027 for these regional and national markets:
– North America: US, Canada, Mexico
– South America: Brazil, Argentina, Paraguay, Brazil, Rest of South America
– Europe: The UK, Germany, France, Spain, Italy, Rest of Europe
– Asia-Pacific: China, Japan, India, Australia, Thailand, Rest of Asia-Pacific
– Rest of World: Middle East, Africa, Other Countries

• This report discusses trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT). It also analyses social, technological, economic and political factors (STEP) that influence the cancer-treating drugs market

World Cancer-Treating Drugs Market Forecast 2017-2027

• Our study discusses the selected leading companies that are the major players in the cancer-treating drugs market:
– AstraZeneca
– Merck & Co., Inc. (Merck)
– Novartis
– Amgen
– Bristol-Myers Squibb (BMS)
– GlaxoSmithKline (GSK)
– Johnson & Johnson (J&J)
– Roche
– Eli Lilly
– Celgene

The report provides overviews of the companies, financial information, product portfolio, pipeline products and recent developments.

Visiongain’s study is intended for anyone requiring commercial analyses for the world cancer-treating drugs market. You find data, trends and predictions.

Buy our report today World Cancer-Treating Drugs Market Forecast 2017-2027: Immunotherapy, Chemotherapy, Targeted Therapy, Hormone Therapy, Leading Drugs.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for World Cancer-Treating Drugs Market Forecast 2017-2027


Download sample pages

Complete the form below to download your free sample pages for World Cancer-Treating Drugs Market Forecast 2017-2027


Latest Pharma news

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021

READ

Visiongain Publishes Anaesthesia & Respiratory Devices Market Report 2020-2030

The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.

07 January 2021

READ

Visiongain Publishes Inactivated Vaccines Market Report 2020-2030

Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.

07 January 2021

READ

Visiongain Publishes Human Microbiome Therapeutics Market Report 2021-2031

The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.

06 January 2021

READ

Categories

Category